Effects of anti‑CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano‑particles on the treatment of ovarian cancer

Yang,Yizhuo; Zhao,Xinghui; Li,Xiuli; Yan,Zhifeng; Liu,Zhongyu; Li,Yali

doi:10.3892/ol.2016.5413

Effects of anti‑CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano‑particles on the treatment of ovarian cancer

Authors:
- Yizhuo Yang
- Xinghui Zhao
- Xiuli Li
- Zhifeng Yan
- Zhongyu Liu
- Yali Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, General Hospital of PLA, Beijing 100853, P.R. China, State Key Laboratory of Pathogens and Biosecurity, Laboratory of Applied Molecular Biology, Beijing Institute of Microbiology and Epidemiology, Beijing 100853, P.R. China
Published online on: November 22, 2016 https://doi.org/10.3892/ol.2016.5413
Pages: 99-104
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Failure in early diagnosis and ineffective treatment are the major causes of ovarian cancer mortality. Hyaluronan and its receptor, cluster of differentiation (CD)44, have been considered to be valid targets for treating cancer. The anti‑CD44 monoclonal antibody IM7 is effective in treating ovarian cancer; however, its toxicity should not be ignored. The present study has developed a new drug carrier system composed of chitosan nano‑particles coated with polylactic acid (PLA) to improve the treatment efficacy and reduce toxicity. An ionic crosslinking method and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysuccinimide were used to prepare the IM7 antibody, which was loaded with chitosan nano‑particles. The surfaces of the nano‑particles were coated with PLA to generate PLA‑chitosan‑IM7. Subsequently, transmission electron microscopy (TEM) was used to observe the size and zeta potential of the nano‑particles. In addition, a spectrophotometer was used to calculate the loading rate and release rate of the nano‑particles in acidic and neutral environments. MTT assay was used to evaluate the anti‑proliferative effect of PLA‑chitosan‑IM7 on the human ovarian cancer cell line HO‑8910PM. In addition, an in vivo imaging system was used to further investigate the effect of PLA‑chitosan‑IM7 on the treatment of mice with ovarian cancer. A total of 35 days subsequent to PLA‑chitosan‑IM7 treatment, all animals were sacrificed by CO2, and the tumors were removed and weighted. The PLA‑chitosan‑IM7 nano‑particles were successfully prepared, since TEM revealed that their size was 300‑400 nm and their zeta potential was +25 mV. According to the spectrophotometry results, the loading rate was 52%, and PLA‑chitosan‑IM7 exhibited good resistance to acids. MTT assay demonstrated that PLA‑chitosan‑IM7 could suppress the proliferation of HO‑8910PM cells in vitro. The in vivo imaging system revealed that PLA‑chitosan‑IM7 was effective in controlling the development of human ovarian cancer cells and the tumor weight. These results suggest that PLA‑chitosan‑IM7 could be effective in treating cancers in vitro and in vivo, which may provide a novel approach to enhance the effectiveness of anti-CD44 treatment while reducing its toxicity.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA and Hung MC: Hyaluronan promotes Cd44V3-Vav2 interaction with Grb2-p185 (HER2) and induces Racl and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 276:48679–48692. 2001. View Article : Google Scholar : PubMed/NCBI
3	Carpenter PM and Dao AV: The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells. Anticancer Res. 23:3985–3990. 2003.PubMed/NCBI
4	Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J and Ottensmeier C: CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors. J Clin Oncol. 13:1912–1921. 1995.PubMed/NCBI
5	Ourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA and Hung MC: Hyaluronan promotes Cd44V3-Vav2 interaction with Grb2-p185(HER2) and induces Racl and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 276:48679–48692. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L and Huang MC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem. 272:27913–27918. 1997. View Article : Google Scholar : PubMed/NCBI
7	Ourguignon LY, Zhu H, Shao L and Chen YW: CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependdent ovarian tumor cell migration. J Biol Chem. 276:7327–7336. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bourguignon LY, Peyrollier K, Gilad E and Brightman A: Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J Biol Chem. 282:1265–1280. 2007. View Article : Google Scholar : PubMed/NCBI
9	Bourugnon LY, Gilad E and Peyrollier K: Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem. 282:19426–19441. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhu D and Bourguignon LY: Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian tumor cell migration. J Cell physiol. 183:182–195. 2000. View Article : Google Scholar : PubMed/NCBI
11	Tzuman YC, Sapoznik S, Granot D, Nevo N and Neeman M: Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: The role of gonadoptropins. Neoplasia. 12:51–60. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ween MP, Hummitzsch K, Roggers RJ, Oehler MK and Ricciardelli C: Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis. 28:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lee H, Lee K and Park TG: Hyaluronic acid-paclitaxel conjugate micelles: Syhthesis, characterization, and antitumor activity. Bioconjug Chem. 19:1319–1325. 2008. View Article : Google Scholar : PubMed/NCBI
14	Cohen MS, Cai S, Xie Y and Forrest ML: A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg. 198:781–786. 2009. View Article : Google Scholar : PubMed/NCBI
15	Banzato A, Bibisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P and Rosato A: A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res. 14:3598–3606. 2008. View Article : Google Scholar : PubMed/NCBI
16	Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, et al: Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 9:3052–3064. 2010. View Article : Google Scholar : PubMed/NCBI
17	Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M and Alemany R: Hyaluronidase expression by an oncolytic adenovrirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 18:1275–1283. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lee SJ, Min HS, Ku SH, Son S, Kwon IC, Kim SH and Kim K: Tumor-targeting glycol chitosan nanoparticles as a platform delivery carrier in cancer diagnosis and therapy. Nanomedicine Lond). 9:1697–1713. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Zhu X, Zhang X, Liu B and Huang L: Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 18:1650–1656. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sun X, Zeng L, Chen C, Huang Y, Han F, Xiao W, Liu S and Lu T: Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients. Radiat Oncol. 8:2652013. View Article : Google Scholar : PubMed/NCBI
21	Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A and Breunig M: Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 9:2059–2064. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cai L, Li J, Zhang X, Lu Y, Wang J, Lyu X, Chen Y, Liu J, Cai H, Wang Y and Li X: Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma. Oncotarget. 6:7838–7850. 2015. View Article : Google Scholar : PubMed/NCBI
23	Biswas S and Torchilin VP: Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev. 66:26–41. 2014. View Article : Google Scholar : PubMed/NCBI